Project description:Extracellular vesicles, including exosomes, and exomere nanoparticles, are under intense investigation for cargo that may serve as clinical biomarkers or therapeutic targets. Here, we report discovery of a new extracellular nanoparticle, termed supermeres. We performed LC/MS-MS proteomics analyses on gradient-purified sEVs, NVs, exomeres and supermeres. The proteomic profile of supermeres is clearly distinct from that of sEVs, NVs and exomeres. This study identifies a new functional nanoparticle replete with potential circulating biomarkers and therapeutic targets that can be exploited for clinical benefit in a host of diseases.
Project description:RNA-Seq of cellular and extracellular samples from DiFi cells. The distribution of extracellular RNA among cells, sEV pellet, exomeres and supermeres is distinct.
Project description:Glioblastoma is a grade IV glioma of heterogeneous nature which complicates disease pathophysiology and biomarker research. Thus, the aim of our meta-analysis is to identify long noncoding RNAs (lncRNAs) and protein coding genes (PCGs) that are differentially expressed over different glioblastoma tissue datasets. Small RNA-seq of glioblastoma tissues was also performed to identify differentially expressed microRNAs (miRNAs) relative to paired controls.
Project description:Extracellular vesicles, including exosomes, and exomere nanoparticles, are under intense investigation for cargo that may serve as clinical biomarkers or therapeutic targets. Here, we report discovery of a new extracellular nanoparticle, termed supermeres. We performed LC/MS-MS proteomics analyses on gradient-purified sEVs, NVs, exomeres and supermeres. The proteomic profile of supermeres is clearly distinct from that of sEVs, NVs and exomeres This study identifies a new functional nanoparticle replete with potential circulating biomarkers and therapeutic targets that can be exploited for clinical benefit in a host of diseases.
Project description:Glioblastoma, the most aggressive form of brain cancer, remains a significant global contributor to mortality. Predictions of its increasing incidence in the coming decades underscore the need for more effective treatment strategies. Caerin 1.1 and 1.9, host defence peptides originally isolated from the skin secretions of an Australian tree frog, have exhibited tumour growth inhibition against a diverse spectrum of tumours in vitro. In this study, we reaffirm their potential by demonstrating their inhibitory impact on glioblastoma growth through CCK8 assays. Furthermore, caerin 1.1 and 1.9 effectively curtailed the migration of all tested glioblastoma cells in a cell scratch assay.Quantitative proteomic analysis was employed to investigate the molecular mechanism underlying the anti-proliferative activity.
